Hi! My name is Nathaniel and I’m a junior at Harvard studying molecular biology.

I’ll be writing a series of essays about my encounters with cutting-edge science, biomedical entrepreneurship and venture capital.

My work is guided by the belief that advances in the life sciences will fundamentally alter our world and have the unique potential to transform our conception of what it means to be human.

I study the science, business, and bioethics of emergent technologies because I want to be a part of that journey — and help to ensure we take the right path.

This winter, I founded Nivien Therapeutics, a biotech company developing an experimental therapy for pancreatic cancer at the Harvard Innovation Labs.

I’m also working on a thesis in the David Sinclair Lab at Harvard Medical School (interventions to slow aging) and growing life sciences deal flow as a partner at First Round Capital’s university venture group Dorm Room Fund.

I write about more quotidian matters like politics and college in The Boston Globe, The New York Times, The Harvard Crimson, and Town & Country.

Keep an eye out for my future essays and feel free to get in touch.

—NBH

Update: Nivien shut down after 2 years. Read our story in The Washington Post.

Principal at RA Capital, on the boards of 7 biotech companies. Founder/CEO of Nivien Therapeutics. Australian-American. 50 countries and counting.

Principal at RA Capital, on the boards of 7 biotech companies. Founder/CEO of Nivien Therapeutics. Australian-American. 50 countries and counting.